Thanks to hefty sales increases from kidney disease drug Kerendia and prostate cancer treatment Nubeqa, Bayer’s pharma ...

Bayer on Tuesday posted a smaller decline in first-quarter adjusted earnings than investors had feared as strong prescription ...

Bayer’s strong first quarter performance was mainly driven by its pharmaceuticals division, even as its crop-science branch ...

Bayer Q1 profit declined to $1.45 billion, but earnings and sales topped estimates as pharma growth offset crop science headwinds and currency impacts.

Meanwhile, Bayer CEO Bill Anderson said Donald Trump’s Most Favored Nations policy could present an opportunity for European ...

Bayer shares jumped after the company reported better-than-expected sales and adjusted earnings for the first quarter, with ...

Bayer chief executive Bill Anderson has said that newer product launches have offset the decline in sales of anticoagulant ...

Nowadays, drugs go through extensive testing before being released to the public. It’s at least unlikely that anything you’re ...

An assessment by UBS says Bristol Myers Squibb and Pfizer would be worst hit among US companies if Mr Trump’s threatened ...

Bayer said an adverse verdict in a US glyphosate lawsuit, which it is appealing against, had added to litigation costs. The company has also filed a petition with the US Supreme Court and has ...

The German maker of drugs and farming pesticides has struggled recently with weak earnings, rising legal costs and a lagging share price. A spokesperson confirmed that Bayer was exiting the ...

Bayer has today posted a slower decline in first-quarter adjusted earnings than the market had feared as strong prescription ...